View in EDS PDF Full Text

Perfil epidemiológico y molecular de pacientes con cáncer de pulmón en un centro oncológico referencial de Lima, Perú.

Saved in:
Bibliographic Details
Title: Perfil epidemiológico y molecular de pacientes con cáncer de pulmón en un centro oncológico referencial de Lima, Perú.
Alternate Title: Epidemiological and molecular profile of lung cancer patients in a referral cancer center in Lima, Peru.
Authors: Motta-Guerrero, Rodrigo1,2, Huerta-Collado, Yesenia1,3, Failoc-Rojas, Virgilio E.1,4 virgiliofr@gmail.com, Cabezas-Orellana, Diego C.1,5, León Garrido-Lecca, Alejandro1, Calle-Villavicencio, Ana1, Torres-Mera, Alicia6,7, Valladares-Garrido, Mario J.8, Aliaga Macha, Carlos1,9, Carracedo, Carlos1
Source: Revista del Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo. 2023, Vol. 16 Issue 3, p1-6. 6p.
Abstract (English): Background: According to GLOBOCAN estimates, in 2020, lung cancer was the second most frequent cancer and epidemiological information is needed in Latin American countries. The objective was to describe the epidemiological and molecular characteristics of lung cancer patients from a referral clinic in Lima, Peru. Material and methods: A retrospective cohort study was conducted to characterize the epidemiological and molecular profile of lung cancer patients attended at a referral cancer center in Peru during 2018 to 2021. Variables such as age, sex, histology, staging and mutation were reported. In the descriptive analysis, frequencies and percentages were shown for categorical variables. For numerical variables, the best measure of central tendency and dispersion was reported. Results: A total of 225 patients with a diagnosis of lung cancer were observed. EGFR gene mutation was the most frequently detected (45.3%); and within them exon 19 deletion (55.7%). The most frequent histological type was adenocarcinoma with 180 patients (85.7%). Of the total number of patients with EGFR mutation, 77.8% received treatment with a tyrosine kinase inhibitor (osimertinib, erlotinib, afatinib) and 15.9% received immunotherapy (pembrolizumab, atezolizumab, nivolumab). Conclusions: The predominant mutation was EGFR, the most frequent histologic type was adenocarcinoma and most patients received treatment with a tyrosine kinase inhibitor. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Introducción: Según estimaciones del GLOBOCAN, en 2020, el cáncer de pulmón fue el segundo más frecuente y se necesita información epidemiológica en países latinoamericanos. El objetivo fue describir las características epidemiológicas y moleculares de pacientes con cáncer de pulmón de una clínica referencial de Lima, Perú. Material y métodos: Se realizó un estudio cohorte retrospectiva para caracterizar el perfil epidemiológico y molecular de los pacientes con cáncer pulmón atendidos en un centro oncológico referencial del Perú durante 2018 al 2021. Se reportaron variables como edad, sexo, histología, estadiaje y mutación. En el análisis descriptivo, se mostraron frecuencias y porcentajes para las variables categóricas. En el caso de las variables numéricas, se reportó la mejor medida de tendencia central y de dispersión. Resultados: Se observó un total de 225 pacientes con diagnóstico de cáncer de pulmón. La mutación del gen EGFR fue la más frecuentemente detectada (45.3%); y dentro de ellas la deleción del exón 19 (55.7%). El tipo histológico más frecuente fue de Adenocarcinoma con 180 pacientes (85.7%). Del total de paciente con mutación en el EGFR, el 77.8% recibió tratamiento con algún inhibidor de tirosin kinasa (osimertinib, erlotinib, afatinib) y un 15.9% recibieron inmunoterapia (pembrolizumab, atezolizumab, nivolumab). Conclusiones: La mutación predominante fue el EGFR, el tipo histológico más frecuente fue el adenocarcinoma y la mayoría de pacientes recibió tratamiento con un inhibidor de tirosin kinasa. [ABSTRACT FROM AUTHOR]
Copyright of Revista del Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo is the property of Cuerpo Medico del Hospital Nacional Almanzor Aguinaga Asenjo and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
Description
Abstract:Background: According to GLOBOCAN estimates, in 2020, lung cancer was the second most frequent cancer and epidemiological information is needed in Latin American countries. The objective was to describe the epidemiological and molecular characteristics of lung cancer patients from a referral clinic in Lima, Peru. Material and methods: A retrospective cohort study was conducted to characterize the epidemiological and molecular profile of lung cancer patients attended at a referral cancer center in Peru during 2018 to 2021. Variables such as age, sex, histology, staging and mutation were reported. In the descriptive analysis, frequencies and percentages were shown for categorical variables. For numerical variables, the best measure of central tendency and dispersion was reported. Results: A total of 225 patients with a diagnosis of lung cancer were observed. EGFR gene mutation was the most frequently detected (45.3%); and within them exon 19 deletion (55.7%). The most frequent histological type was adenocarcinoma with 180 patients (85.7%). Of the total number of patients with EGFR mutation, 77.8% received treatment with a tyrosine kinase inhibitor (osimertinib, erlotinib, afatinib) and 15.9% received immunotherapy (pembrolizumab, atezolizumab, nivolumab). Conclusions: The predominant mutation was EGFR, the most frequent histologic type was adenocarcinoma and most patients received treatment with a tyrosine kinase inhibitor. [ABSTRACT FROM AUTHOR]
ISSN:22255109
DOI:10.35434/rcmhnaaa.2023.163.1805